Scholarlink

<p>The development of innovative antitumor formulations that are able to increase the mortality of cancer cells while decreasing the efficacious pharmacological dosage is a fundamental goal of modern oncological research. In this study a paclitaxel (PTX)-nanomedicine was tested on two lines of human high-grade serous ovarian carcinoma (hHGS-OC). Zein, a vegetal protein, was employed to obtain nanoparticles containing the lipophilic compound (NanoPTX) characterized by a mean diameter of 160&#xa0;nm, a narrow size distribution, a negative zeta potential and a prolonged release of the drug over time. NanoPTX was tested on HEY and COV362 cells demonstrating an increase of apoptosis, particularly on the papillary cystadenocarcinoma cells (55.2% <i>p</i> value 0.037 for NanoPTX vs 70.25%, <i>p</i> value 0.08 for PTX) with respect to the free form of the drug. The fluorescent nanosystems were characterized by a significant cell uptake after a few hours of incubation and they promoted a reduction in the intracellular reactive oxygen species. The results need to be validated on different hHGS-OC cells and the real efficacy of the proposed nanomedicine needs to be investigated using in vivo models of ovarian carcinoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the effects of paclitaxel-loaded zein nanoparticles on human ovarian carcinoma cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月27日

查看全文
  • Stefania Scicchitano,
  • Agnese Gagliardi,
  • Nicola Ambrosio,
  • Eleonora Vecchio,
  • Cinzia Garofalo,
  • Anna Martina Battaglia,
  • Francesco Saverio Costanzo,
  • Maria Concetta Faniello,
  • Donato Cosco

摘要

The development of innovative antitumor formulations that are able to increase the mortality of cancer cells while decreasing the efficacious pharmacological dosage is a fundamental goal of modern oncological research. In this study a paclitaxel (PTX)-nanomedicine was tested on two lines of human high-grade serous ovarian carcinoma (hHGS-OC). Zein, a vegetal protein, was employed to obtain nanoparticles containing the lipophilic compound (NanoPTX) characterized by a mean diameter of 160 nm, a narrow size distribution, a negative zeta potential and a prolonged release of the drug over time. NanoPTX was tested on HEY and COV362 cells demonstrating an increase of apoptosis, particularly on the papillary cystadenocarcinoma cells (55.2% p value 0.037 for NanoPTX vs 70.25%, p value 0.08 for PTX) with respect to the free form of the drug. The fluorescent nanosystems were characterized by a significant cell uptake after a few hours of incubation and they promoted a reduction in the intracellular reactive oxygen species. The results need to be validated on different hHGS-OC cells and the real efficacy of the proposed nanomedicine needs to be investigated using in vivo models of ovarian carcinoma.